FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine, namely to oncology, and can be used to treat cancer. According to the invention, these pharmaceutical combination, method, use and pharmaceutical composition are intended for the treatment of cancer and include the introduction of (2-hydroxyethoxy)-amide 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (compound A) and antibodies A, containing the amino acid sequence of the heavy and light chains presented in SEQ ID NO: 1 and SEQ ID NO: 2, respectively.
EFFECT: use of the inventions makes it possible to treat cancer due to the synergistic effect of the combination of compound A and antibody A with respect to cell proliferation.
20 cl, 1 dwg, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMBINATIONS | 2017 |
|
RU2759669C2 |
| THERAPEUTIC COMBINATIONS CONTAINING RAF INHIBITOR AND ERK INHIBITOR | 2017 |
|
RU2774612C2 |
| SYNERGISTIC COMBINATIONS OF PI3K- AND MEK-INHIBITORS | 2012 |
|
RU2607944C2 |
| PHARMACEUTICAL COMPOUND | 2018 |
|
RU2786994C2 |
| COMBINATION THERAPY | 2018 |
|
RU2815400C2 |
| MDM2 INHIBITORS AND COMBINATIONS THEREOF | 2016 |
|
RU2740091C2 |
| METHOD OF TREATING CANCER CARRYING EGFR MUTATIONS | 2007 |
|
RU2492864C2 |
| PHARMACEUTICAL COMBINATION CONTAINING TNO155 AND RIBOCICLIB | 2020 |
|
RU2813111C2 |
| TETRAHYDROFOLATES IN COMBINATION WITH EGFR INHIBITORS | 2013 |
|
RU2619335C2 |
| COMBINATION OF (A) PHOSPHOINOSITIDE-3-KINASE INHIBITOR AND (B) Ras/Raf/Mek PATHAWAY MODULATOR | 2009 |
|
RU2508110C2 |
